Compare Quest Diagnostics Inc (DGX) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Zillow Group Inc Class C — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Zillow Group Inc Class C trades at $33.74 (market cap $7.28B). The key difference: Quest Diagnostics Inc is far larger — about 3.1× Zillow Group Inc Class C's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| DGX | Z | |
|---|---|---|
Market Cap | $22.80B | $7.28B |
Sector | Health | Media |
52-Week High | $216.02 | $90.35 |
52-Week Low | $166.42 | $29.41 |
Enterprise Value | $28.82B | $6.93B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Zillow Group Inc. (Z) trades at $32.19 with no daily change, reflecting a bearish technical signal amid ongoing class action lawsuits. The company shows improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though net margins remain thin at 2.27%. Valuation ratios are elevated with a P/E of 127.4, while analyst consensus targets $57.67, implying significant upside if legal and operational risks subside.
The stock presents a high-risk, high-reward scenario. Positive earnings beats and projected margin expansion to 2.26% in 2026 support bullish fundamentals, but legal overhangs and negative cash flow trends pose near-term headwinds. Institutional sentiment is mixed with 46% buy ratings, suggesting cautious optimism contingent on resolution of litigation and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
